Junxian Cao
Beijing, 100700, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The CETSA-Luminex integrated platform for drug targets screening identifies IL-4-IN-1 as an anti-pulmonary fibrosis therapeutic candidate.
Journal: Biochemical and biophysical research communications
Published: July 01, 2025
Synergistic multi-target anti-inflammatory mechanisms of luteolin, chikusetsusaponin IVa and carabrone in Houyanqing formula.
Journal: Journal of ethnopharmacology
Published: January 27, 2025
Correction: Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.
Journal: Cell death & disease
Published: July 24, 2024
Advances in human cellular mechanistic understanding and drug discovery of brain organoids for neurodegenerative diseases.
Journal: Ageing research reviews
Published: March 13, 2024
Spatial Transcriptomics: A Powerful Tool in Disease Understanding and Drug Discovery.
Journal: Theranostics
Published: March 04, 2024
Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.
Journal: Cell death & disease
Published: December 22, 2023
Organ-on-a-chip meets artificial intelligence in drug evaluation.
Journal: Theranostics
Published: June 17, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026